Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease

Valeriya Pozdnyakova¹, Gregory J Botwin¹, Kimia Sobhani², John Prostko³, Jonathan Braun¹, Dermot P B Mcgovern¹, Gil Y Melmed⁴, Keren Appel¹, Andrea Banty¹, Edward Feldman¹, Christina Ha¹, Rashmi Kumar¹, Susie Lee¹, Shervin Rabizadeh¹, Theodore Stein¹, Gaurav Syal¹, Stephan Targan¹, Eric Vasiliauskas¹, David Ziring¹, Philip Debbas¹, Melissa Hampton¹, Emebet Mengesha¹, James L Stewart³, Edwin C Frias³, Susan Cheng⁵, Joseph Ebinger⁵, Jane C Figueiredo⁶, Brigid Boland⁷, Aline Charabaty⁸, Michael Chiorean⁹, Erica Cohen¹⁰, Ann Flynn¹¹, John Valentine¹¹, David Fudman¹², Arash Horizon¹³, Jason Hou¹⁴, Caroline Hwang¹⁵, Mark Lazarev¹⁶, Donald Lum¹⁷, Rebecca Fausel¹⁷, Swapna Reddy¹⁷, Mark Mattar¹⁸, Mark Metwally¹⁹, Arthur Ostrov¹⁹, Nimisha Parekh²⁰, Laura Raffals²¹, Sarah Sheibani²², Corey Siegel²³, Douglas Wolf²⁴, Ziad Younes²⁵

Affiliations

¹ Inflammatory Bowel and Immunobiology Research Institute, Karsh Division of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
² Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
³ Applied Research and Technology, Abbott Diagnostics, Abbott Park, Illinois.
⁴ Inflammatory Bowel and Immunobiology Research Institute, Karsh Division of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California. Electronic address: gil.melmed@cshs.org.
⁵ Smidt Heart Institute, Department of Medicine, Cedars-Sinai, Los Angeles, California.
⁶ Samual Oschin Comprehensive Cancer Center, Cedars-Sinai, Los Angeles, California.
⁷ University of California, San Diego, California.
⁸ Sibley Memorial Hospital, Johns Hopkins, Washington, District of Columbia.
⁹ Swedish Hospital, Seattle, Washington.
¹⁰ Capital Digestive Care, Chevy Chase, Maryland.
¹¹ University of Utah, Salt Lake City, Utah.
¹² UT Southwestern, Dallas, Texas.
¹³ Center for Rheumatology, Los Angeles, California.
¹⁴ Baylor College of Medicine, Houston, Texas.
¹⁵ Hoag Hospital, Newport Beach, California.
¹⁶ Johns Hopkins Hospital, Baltimore, Maryland.
¹⁷ The Oregon Clinic, Portland, Oregon.
¹⁸ Medstar-Georgetown, Washington, District of Columbia.
¹⁹ Saratoga-Schenectady Gastroenterology, Saratoga Springs, New York.
²⁰ University of California, Irvine, California.
²¹ The Mayo Clinic, Rochester, Minnesota.
²² Keck Medicine of University of Southern California, Los Angeles, California.
²³ Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
²⁴ Atlanta Gastroenterology Associates, Atlanta, Georgia.
²⁵ Gastro One, Germantown, Tennessee.

PMID: 34391771
PMCID: PMC8359492
DOI: 10.1053/j.gastro.2021.08.014

Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease

Valeriya Pozdnyakova et al. Gastroenterology. 2021 Dec.

. 2021 Dec;161(6):2041-2043.e1.

doi: 10.1053/j.gastro.2021.08.014. Epub 2021 Aug 12.

Authors

Affiliations

¹ Inflammatory Bowel and Immunobiology Research Institute, Karsh Division of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
² Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
³ Applied Research and Technology, Abbott Diagnostics, Abbott Park, Illinois.
⁴ Inflammatory Bowel and Immunobiology Research Institute, Karsh Division of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California. Electronic address: gil.melmed@cshs.org.
⁵ Smidt Heart Institute, Department of Medicine, Cedars-Sinai, Los Angeles, California.
⁶ Samual Oschin Comprehensive Cancer Center, Cedars-Sinai, Los Angeles, California.
⁷ University of California, San Diego, California.
⁸ Sibley Memorial Hospital, Johns Hopkins, Washington, District of Columbia.
⁹ Swedish Hospital, Seattle, Washington.
¹⁰ Capital Digestive Care, Chevy Chase, Maryland.
¹¹ University of Utah, Salt Lake City, Utah.
¹² UT Southwestern, Dallas, Texas.
¹³ Center for Rheumatology, Los Angeles, California.
¹⁴ Baylor College of Medicine, Houston, Texas.
¹⁵ Hoag Hospital, Newport Beach, California.
¹⁶ Johns Hopkins Hospital, Baltimore, Maryland.
¹⁷ The Oregon Clinic, Portland, Oregon.
¹⁸ Medstar-Georgetown, Washington, District of Columbia.
¹⁹ Saratoga-Schenectady Gastroenterology, Saratoga Springs, New York.
²⁰ University of California, Irvine, California.
²¹ The Mayo Clinic, Rochester, Minnesota.
²² Keck Medicine of University of Southern California, Los Angeles, California.
²³ Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
²⁴ Atlanta Gastroenterology Associates, Atlanta, Georgia.
²⁵ Gastro One, Germantown, Tennessee.

PMID: 34391771
PMCID: PMC8359492
DOI: 10.1053/j.gastro.2021.08.014

No abstract available

PubMed Disclaimer

Figures

**Figure 1**
(A) Percentage of participants with a positive anti-Spike IgG value (≥50 AU/mL) based on vaccine type at least 2 weeks after regimen completion. (B) Log₁₀(anti-spike IgG value) among participants receiving Ad26.CoV2.S (Johnson & Johnson), mRNA-1273 (Moderna/National Institutes of Health), and BNT162b2 (Pfizer-BioNTech) vaccines at 3 time points: after regimen completion (2–13 days after completing regimen), week 2 (14–29 days after completing regimen), and week 8 (42–84 days after completing regimen). *Dotted line* represents manufacturer set anti-spike IgG positivity threshold (>50 AU/mL).

See this image and copyright information in PMC

References

1. Kappelman MD, et al. Gastroenterology 2021;161:1340–1343.e2. - PMC - PubMed
1. Kennedy NA, et al. Gut 2021;70:1884–1893. - PubMed
1. Wong S.Y., et al. Gastroenterology. 2021;161:715–718.e4. - PMC - PubMed
1. Boyarsky B.J., et al. Transplantation. 2021;105:e8–e83. - PMC - PubMed
1. Werbel WA, et al. Ann Intern Med 2021; 10.7326/L21-0282. - DOI - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease

Affiliations

Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease

Authors

Affiliations

Figures

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous